The results of this randomized double blind, placebo controlled trial of a single oral dose of 2 g tinidazole or placebo approximately 12 hours before hysterectomy showed the incidence of infective morbidity in patients who received placebo was 12.2% compared with 1.9% in patients who received tinidazole, (p = 0.045). The mean serum concentration of tinidazole at the time of surgery was 35 mcg/ml, which was well in excess of the minimum concentration required to inhibit all of the 95 anaerobes isolated in this study. Serum tinidazole concentration remained adequately inhibitory for at least 24 hours after surgery. The ability of tinidazole prophylaxis to reduce further our already low rate of febrile morbidity was considered a worthwhile gain. It is now Unit policy to give this agent prophylactically to all patients if the integrity of the vagina is likely to be breached at the time of surgery.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1479-828x.1985.tb00604.x | DOI Listing |
Sex Transm Dis
February 2025
From the Division of Infectious Diseases, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, OH.
A 30-year-old male patient with symptomatic Mycoplasma genitalium urethritis failed treatment with oral azithromycin, 2-stage doxycycline-moxifloxacin, and minocycline. Molecular testing confirmed the presence of macrolide resistance mutations. Treatment with oral tinidazole 2 g daily for 7 days resulted in clinical and microbiologic cure.
View Article and Find Full Text PDFEur J Drug Metab Pharmacokinet
September 2024
Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, 510080, China.
Background And Objectives: Smoothened (SMO), a key component of the hedgehog signaling pathway, represents a therapeutic target for triple negative breast cancer (TNBC), yet the chemotherapy response rate in TNBC patients is only 40-50%, underscoring the urgent need for the development of novel drugs to effectively treat this condition. The novel compound TPB15, an SMO inhibitor derived from [1,2,4] triazolo [4,3-α] pyridines, demonstrated superior anti-TNBC activity and lower toxicity compared to the first SMO inhibitor vismodegib in both in vitro and in vivo. However, the compound's pharmacokinetic properties remain unclear.
View Article and Find Full Text PDFDrugs R D
June 2024
Research Center of Beijing Fuyuan Pharmaceutical Co., Ltd., Beijing, 101113, People's Republic of China.
Background And Objective: Ornidazole, the third generation of nitroimidazole derivatives after metronidazole and tinidazole, it exerts both bactericidal and antiprotozoal effects. The purpose of this study was to evaluate the pharmacokinetic and bioequivalence of two ornidazole tablets manufactured by two different manufacturers based on their pharmacokinetic parameters.
Patients And Methods: Fasted and fed healthy Chinese volunteers participated in a randomized sequence, single-dose, open-label, two-period crossover trial.
Acta Trop
July 2024
Nutritional Health Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran. Electronic address:
Reportedly, synthetic drugs such as metronidazole, furazolidone, tinidazole, and quinacrine are used for the treatment of giardiasis but are associated with adverse effects. In this study, we aimed to investigate the in vitro and in vivo effects of eucalyptol (ECT, 1,8 cineole) alone and in combination with metronidazole (MNZ) on Giardia lamblia. The effects of ECT on cell viability, plasma membrane permeability, and gene expression levels of adenylate cyclase (AK) and extracellular signal kinases 1 and 2 (ERK1 and ERK2) in trophozoites of G.
View Article and Find Full Text PDFHealth Sci Rep
January 2024
Department of Infectious Diseases, School of Medicine Isfahan University of Medical Sciences Isfahan Iran.
Backgrounds And Aims: This controlled randomized clinical trial was designed to compare effectiveness, side effects, and severity of symptoms before and after therapy between quadruple (QT) and sequential regimens (SQ) for ().
Methods: Patients were randomly allocated into two groups. Group A received a 14-day QT including pantoprazole 40 mg q12 h, bismuth subcitrate 240 mg q12 h, clarithromycin 500 mg q12 h, and amoxicillin 1000 mg q12 h and group B received ST including pantoprazole 40 mg q12 h and amoxicillin 1000 mg q12 h for the initial 5 days followed by pantoprazole 40 mg q12 h, clarithromycin 500 mg q12 h and tinidazole 500 mg q12 h for the next 5 days.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!